Bill Sponsor
House Bill 2918
115th Congress(2017-2018)
Patients First Act of 2017
Introduced
Introduced
Introduced in House on Jun 15, 2017
Overview
Text
Sponsor
Introduced
Jun 15, 2017
Latest Action
Jun 16, 2017
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
2918
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
Indiana
Republican
California
Republican
Colorado
Republican
Georgia
Democrat
Illinois
Republican
Illinois
Republican
Louisiana
Republican
Maryland
Republican
Mississippi
Republican
Mississippi
Republican
New Jersey
Republican
North Carolina
Republican
North Carolina
Republican
Oklahoma
Republican
Pennsylvania
Republican
Pennsylvania
Republican
South Carolina
Republican
South Carolina
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Patients First Act of 2017

This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, provided that the techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.

HHS must issue guidelines to ensure that any research (including any clinical trial) supported under this bill: (1) is clearly consistent with the standards established in this bill, if conducted using human cells; and (2) is prioritized in terms of potential for near-term clinical benefit in human patients.

HHS must report on peer reviewed stem cell research proposals that were not funded.

Text (1)
June 15, 2017
Actions (3)
06/16/2017
Referred to the Subcommittee on Health.
06/15/2017
Referred to the House Committee on Energy and Commerce.
06/15/2017
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:37:50 PM